Science News
from research organizations

Strong Immune Response To New SiRNA Drugs In Development May Cause Toxic Side Effects

Date:
May 25, 2009
Source:
Mary Ann Liebert, Inc./Genetic Engineering News
Summary:
Small synthetic fragments of genetic material called small interfering RNA (siRNA) can block production of abnormal proteins; however, these exciting new drug candidates can also induce a strong immune response, causing toxic side effects.
Share:
       
FULL STORY

Small synthetic fragments of genetic material called small interfering RNA (siRNA) can block production of abnormal proteins; however, these exciting new drug candidates can also induce a strong immune response, causing toxic side effects. Understanding how siRNA stimulates this undesirable immune activity, how to test for it, and how to design siRNA drugs to avoid it are critical topics explored in a new review article.

siRNAs are duplex structures comprised of short oligonucleotide sequences. The discovery that naturally occurring and synthetic siRNAs can effectively prevent expression of a disease gene sparked intense interest in developing siRNAs as drugs. However, depending on the structure and sequence of a siRNA and how it is delivered, it may induce a potent innate immune response in humans, stimulating the release of inflammatory chemicals such as cytokines and interferons.

Exploring the possibility of designing synthetic siRNAs and developing novel delivery methods that would exploit the drug-like capabilities of siRNA while preventing toxic side effects, researchers are working to understand the mechanism by which siRNA stimulates the immune system. In the article, Marjorie Robbins, Adam Judge, and Ian MacLachlan, from Tekmira Pharmaceuticals (Burnaby, British Columbia, Canada), describe the different possible mechanisms for siRNA-mediated immune activation in various cell types, present preferable siRNA sequences and strategies for chemically modifying the siRNA to minimize its immunostimulatory effects, and suggest experimental methods for studying the safety of siRNA therapeutics.

The authors conclude, "We are confident that through the judicious application of well-informed siRNA design and the use of increasingly effective delivery systems, demonstrations of systemic siRNA in human subjects will soon be realized."


Story Source:

The above post is reprinted from materials provided by Mary Ann Liebert, Inc./Genetic Engineering News. Note: Materials may be edited for content and length.


Journal Reference:

  1. siRNA and Innate Immunity. Oligonucleotides, (in press)

Cite This Page:

Mary Ann Liebert, Inc./Genetic Engineering News. "Strong Immune Response To New SiRNA Drugs In Development May Cause Toxic Side Effects." ScienceDaily. ScienceDaily, 25 May 2009. <www.sciencedaily.com/releases/2009/05/090520114701.htm>.
Mary Ann Liebert, Inc./Genetic Engineering News. (2009, May 25). Strong Immune Response To New SiRNA Drugs In Development May Cause Toxic Side Effects. ScienceDaily. Retrieved July 28, 2015 from www.sciencedaily.com/releases/2009/05/090520114701.htm
Mary Ann Liebert, Inc./Genetic Engineering News. "Strong Immune Response To New SiRNA Drugs In Development May Cause Toxic Side Effects." ScienceDaily. www.sciencedaily.com/releases/2009/05/090520114701.htm (accessed July 28, 2015).

Share This Page: